Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.
Authors | |
Keywords | |
Abstract | BACKGROUND: While dietary fat has been established as a risk factor for colorectal cancer (CRC), associations between fatty acids (FAs) and CRC have been inconsistent. Using Mendelian randomisation (MR), we sought to evaluate associations between polyunsaturated (PUFA), monounsaturated (MUFA) and saturated FAs (SFAs) and CRC risk. METHODS: We analysed genotype data on 9254 CRC cases and 18,386 controls of European ancestry. Externally weighted polygenic risk scores were generated and used to evaluate associations with CRC per one standard deviation increase in genetically defined plasma FA levels. RESULTS: Risk reduction was observed for oleic and palmitoleic MUFAs (OR = 0.77, 95% CI: 0.65-0.92, P = 3.9 × 10; OR = 0.36, 95% CI: 0.15-0.84, P = 0.018). PUFAs linoleic and arachidonic acid had negative and positive associations with CRC respectively (OR = 0.95, 95% CI: 0.93-0.98, P = 3.7 × 10; OR = 1.05, 95% CI: 1.02-1.07, P = 1.7 × 10). The SFA stearic acid was associated with increased CRC risk (OR = 1.17, 95% CI: 1.01-1.35, P = 0.041). CONCLUSION: Results from our analysis are broadly consistent with a pro-inflammatory FA profile having a detrimental effect in terms of CRC risk. |
Year of Publication | 2017
|
Journal | Eur J Cancer
|
Volume | 84
|
Pages | 228-238
|
Date Published | 2017 10
|
ISSN | 1879-0852
|
DOI | 10.1016/j.ejca.2017.07.034
|
PubMed ID | 28829991
|
PubMed Central ID | PMC5630201
|
Links | |
Grant list | 090532/Z/09/Z / Wellcome Trust / United Kingdom
C1298/A8362 / Cancer Research UK / United Kingdom
U01 CA074799 / CA / NCI NIH HHS / United States
MC_PC_U127527198 / Medical Research Council / United Kingdom
HHSN261201000035C / CA / NCI NIH HHS / United States
U24 CA074783 / CA / NCI NIH HHS / United States
N01 CN067009 / CN / NCI NIH HHS / United States
U24 CA074794 / CA / NCI NIH HHS / United States
N01PC35137 / CA / NCI NIH HHS / United States
U24 CA074806 / CA / NCI NIH HHS / United States
U24 CA097735 / CA / NCI NIH HHS / United States
U01 CA074794 / CA / NCI NIH HHS / United States
HHSN261201300012I / CA / NCI NIH HHS / United States
C348/A12076 / Cancer Research UK / United Kingdom
R01 CA143237 / CA / NCI NIH HHS / United States
N01PC35142 / CA / NCI NIH HHS / United States
MR/K018647/1 / Medical Research Council / United Kingdom
K02 AA018755 / AA / NIAAA NIH HHS / United States
HHSN261201000035I / CA / NCI NIH HHS / United States
K05 AA000145 / AA / NIAAA NIH HHS / United States
U01 CA097735 / CA / NCI NIH HHS / United States
R01 AA012502 / AA / NIAAA NIH HHS / United States
UM1 CA167551 / CA / NCI NIH HHS / United States
U01 CA122839 / CA / NCI NIH HHS / United States
S10 OD020069 / OD / NIH HHS / United States
Wellcome Trust / United Kingdom
U01 CA074783 / CA / NCI NIH HHS / United States
U24 CA074799 / CA / NCI NIH HHS / United States
U01 CA074806 / CA / NCI NIH HHS / United States
U24 CA074800 / CA / NCI NIH HHS / United States
U01 CA074800 / CA / NCI NIH HHS / United States
R37 AA012502 / AA / NIAAA NIH HHS / United States
|